Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | August 19, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date August 19, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 2,778 · Balance 2,778 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Row 2 · 2026-08-19 · Sale · Disposed 2,778 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.36 · Expires 2035-05-22 | Direct | 19,445 |
Reported balance
After 2026-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-19 · Exercise / conversion · Disposed 2,778 · Balance 19,445 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F3: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ra Pharmaceuticals, Inc.
Report date April 02, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 1
1 source rowRow 1 · 2020-04-02 · Disposition to issuer · Disposed 12,595 · Balance 0 F1: Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2026-06-16 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-02 · Disposition to issuer · Disposed 46,434 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2026-06-16 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-02 · Disposition to issuer · Disposed 26,422 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2026-08-16 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-02 · Disposition to issuer · Disposed 67,500 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.33 · Expires 2028-02-02 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-02 · Disposition to issuer · Disposed 55,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-04-02 · Disposition to issuer · Disposed 107,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-04-02 · Disposition to issuer · Disposed 9,166 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020.
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 19, 2026 22:02 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,778 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0001688199-26-000006 · ownership.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,445 Underlying: Common Stock · 2,778 shares Expires 2035-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 19, 2026 Filed Aug 19, 2026 22:02 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,778 | $117.55 | $326,553.90 |
DisclosureSEC source: 0001688199-26-000006 · ownership.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 19, 2026 Filed Aug 19, 2026 22:02 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 2,778 | $18.36 | $51,004.08 |
DisclosureSEC source: 0001688199-26-000006 · ownership.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,777 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · derivative · entry 8 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,223 Underlying: Common Stock · 2,777 shares Expires 2035-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F8 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 397 | $111.77 | $44,372.69 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 7 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.57 to $111.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 470 | $111.05 | $52,193.50 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 6 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.56 to $111.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 272 | $109.96 | $29,909.12 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 5 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.55 to $110.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 831 | $108.95 | $90,537.45 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 4 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,139 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 737 | $108.17 | $79,721.29 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 3 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,970 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.54 to $108.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 70 | $107.11 | $7,497.70 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,707 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.50 to $107.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:10 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 2,777 | $18.36 | $50,985.72 |
DisclosureSEC source: 0001688199-26-000004 · ownership.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001688199-26-000002 · ownership.xml · derivative · entry 1 Read Simon · CIK 0001688199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:40 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076400 · ownership.xml · derivative · entry 1 Read Simon · CIK 0001688199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerRestricted Stock Units · Derivative | 9,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 8 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,166 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 107,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 7 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,000 shares Expires 2029-02-01 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 6 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2028-02-02 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 67,500 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 5 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,500 shares Expires 2027-02-01 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 4 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-08-16 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,422 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,422 shares Expires 2026-06-16 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,434 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · derivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,434 shares Expires 2026-06-16 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerCommon Stock | 12,595 | $48.00 | $604,560.00 |
DisclosureSEC source: 0001104659-20-042770 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 23:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-073911 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 23:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $47.08 | $470,821.00 |
DisclosureSEC source: 0001104659-19-073911 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.05 to $47.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 23:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-073911 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 22:07 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-065128 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 22:07 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $46.68 | $466,808.00 |
DisclosureSEC source: 0001104659-19-065128 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.65 to $46.71. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 22:07 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-065128 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-054728 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $46.87 | $468,726.00 |
DisclosureSEC source: 0001104659-19-054728 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.69 to $46.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 23:00 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-054728 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:43 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-050299 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:43 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $25.41 | $254,050.00 |
DisclosureSEC source: 0001104659-19-050299 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.09 to $26.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:43 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-050299 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 22:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-047565 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 22:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $27.77 | $277,703.00 |
DisclosureSEC source: 0001104659-19-047565 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 22:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-047565 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 23:04 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-041021 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 23:04 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 10,000 | $32.95 | $329,479.00 |
DisclosureSEC source: 0001104659-19-041021 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.57 to $33.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 23:04 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-041021 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:03 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-19-036492 · a4.xml · derivative · entry 4 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,142 Underlying: Common Stock · 10,000 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:03 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 414 | $23.09 | $9,559.51 |
DisclosureSEC source: 0001104659-19-036492 · a4.xml · nonDerivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.00 to $23.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:03 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCOMMON STOCK | 9,586 | $22.21 | $212,907.94 |
DisclosureSEC source: 0001104659-19-036492 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,648 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.00 to $22.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:03 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 10,000 | $2.87 | $28,700.00 |
DisclosureSEC source: 0001104659-19-036492 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:39 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionRestricted Stock Units · Derivative | 9,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005906 · a4.xml · derivative · entry 4 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 9,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: On February 1, 2018, the reporting person was granted 27,500 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:39 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 107,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005906 · a4.xml · derivative · entry 3 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2029-02-01 F2 · derivative.exercise_date: These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:39 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Tax withholdingCOMMON STOCK | 2,933 | $21.00 | $61,593.00 |
DisclosureSEC source: 0001104659-19-005906 · a4.xml · nonDerivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,234 Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:39 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 9,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-005906 · a4.xml · nonDerivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:46 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantRestricted Stock Unit · Derivative | 27,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-006635 · a4.xml · derivative · entry 2 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires not disclosed F2 · derivative.exercise_date: These Restricted Stock Units vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:46 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 55,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-18-006635 · a4.xml · derivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:27 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 67,500 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001104659-17-006441 · a4.xml · derivative · entry 1 Read Simon · CIK 0001688199 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-02-01 F1 · derivative.exercise_date: These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date, provided that the first vesting shall not occur until April 1, 2017, and on such first vesting date, the total number of monthly installments between the grant date and April 1, 2017 shall vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.